Table 1 Summary of patient characteristics at baseline

Patient	Age	Gender	PS	Histotype	First line	Number of lines	Lesions	RT	Failure	TFTF	OR	Duration	Survival
1	66	Male	3	DLC	MVP	2	Single	+	R	5	CR	70.0+	74.0+
2	54	Male	2	DLC	MVP	1	Multiple	+	R	19	PR	2.5	2.5
3	61	Female	0	DLC	MA	1	Multiple	−	R	10	PD		2.0
4	60	Male	2	DLC	MBAVm	1	Multiple	+	R	23	ED		1.5
5	57	Male	3	DLC	MATI	1	Single	−	PD	4	PD		3.5
6	52	Male	3	DLC	CVOD/BVAM	1	Multiple	+	R	11	ED		1.0
7	62	Female	0	DLC	MATI	1	Multiple	+	R	14	PD		1.5
8	54	Male	1	LP	M	1	Multiple	+	PD	10	SD	16.5	54.5+
9	68	Male	2	DLC	none	0	Multiple	+	R	99	PD		4.5
10	64	Male	1	DLC	MATI	1	Single	+	R	12	SD	2.0	2.0
11	51	Male	1	DLC	MA	1	Multiple	+	R	39	CR	2.0	19.0
12	54	Female	2	DLC	F-MACHOPn	2	Multiple	+	R	130	PD		3.5
13	54	Male	2	DLC	MAI	4	Single	+	R	28	PD		2.5
14	64	Female	1	DLC	MVP	1	Multiple	+	R	24	PD		16.0
15	61	Female	2	UN	M	1	Single	+	R	19	CR	17.5+	18.0+
16	62	Male	0	DLC	MVP	1	Single	−	R	14	PD		27.5
17	54	Female	1	DLC	VPAL	1	Multiple	+	R	20	SD	9.5	9.5
18	81	Male	1	UN	MVP	1	Single	−	R	44	CR	6.0	22.5+
19	48	Male	2	UN	MVP	1	Multiple	+	PD	6	ED		1.0
20	66	Male	2	DLC	A	1	Multiple	+	R	48	ED		1.0
21	47	Male	0	DLC	A	1	Single	+	R	14	SD	5.0	25.5+
22	69	Male	4	DLC	MA	1	Single	+	R	38	CR	4.5	7.0
23	56	Female	3	DLC	MA	1	Multiple	+	R	18	PD		0.5
24	75	Male	3	DLC	none	0	Multiple	+	R	21	PR	6.5	9.0
25	59	Female	3	DLC	MATI	1	Multiple	+	PD	9	PD		2.0
26	34	Male	2	DLC	MA,P, PBSCT	3	Multiple	+	PD	20	CR	1.0	5.5
27	36	Male	2	DLC	MABET	2	Multiple	+	PD	1	ED		1.0
28	58	Male	3	DLC	MATI	1	Single	+	R	9	ED		1.5
29	51	Female	2	DLC	M, Me, N, R, PBSCT	1	Multiple	−	R	20	PD		2.0
30	59	Female	2	DLC	MATI	1	Multiple	+	R	8	PD		5.0
31	73	Female	3	DLC	MATI	1	Multiple	+	R	28	CR	20.0+	22.0+
32	54	Female	3	DLC	MATI	1	Multiple	+	R	54	CR	9.5	13.5
33	64	Male	2	DLC	MATI	1	Multple	+	R	12	PD		2.5
34	65	Male	3	HG	MA	2	Multiple	+	PD	8	CR	7.0+	14.0+
35	72	Male	2	DLC	—	—	Single	+	PD	8	SD	5.0	5.5
36	65	Male	2	DLC	M	1	Multiple	+	R	10	PD		1.5

Abbreviations: A=cytarabine; B=carmustine; CR=complete response; D=dexamethasone; DLC=diffuse large B cells; E=etoposide; ED=early death; F=fluorouracil; HG=high grade; I=idarubicin; LP=lymphoplasmacytic; Me=melphalan; M=methotrexate; N=novantrone; O=doxorubicin; OR=overall response; P=procarbazine; PBSCT=peripheral blood stem cell transplantation; PD=progression; Pn=prednisone; PR=partial response; PS=performance status; R=recurrence; Ri=rituximab; RT=radiotherapy; SD=stable disease; T=thiotepa; TFTF=time to first treatment failure; UN=unclassified; V=vincristine.Vm: teniposide; L=lomustine.

Search